Caricamento...
Efficacy of Ruxolitinib for Myelofibrosis
INTRODUCTION: The discovery of the activating JAK2V617F mutation in patients with myelofibrosis (MF) led to the development of JAK2 inhibitors. The first such inhibitor to enter clinical trials was ruxolitinib. This review summarizes pre-clinical and clinical data of ruxolitinib in MF. AREAS COVERED...
Salvato in:
| Pubblicato in: | Expert Opin Pharmacother |
|---|---|
| Autori principali: | , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
2014
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4824286/ https://ncbi.nlm.nih.gov/pubmed/24856675 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1517/14656566.2014.923404 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|